Mersana Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Mersana Therapeutics, Inc. (NASDAQ: MRSN) announced its participation in two investor conferences in August 2020. The company focuses on developing antibody-drug conjugates (ADCs) to treat cancers with significant unmet medical needs. Key events include:

• BTIG Virtual Biotechnology Conference - August 11, 2020, 1:00 p.m. ET (Fireside Chat)
• Wedbush PacGrow Healthcare Virtual Conference - August 12, 2020, 1:45 p.m. ET (Presentation)

Webcasts will be available on Mersana's website, with archived replays for 90 days.

CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that management will present at two upcoming investor conferences. Details are as follows:   

BTIG Virtual Biotechnology Conference 2020
Forum: Fireside Chat
Date/Time: Tuesday, August 11, 2020, at 1:00 p.m. ET

2020 Wedbush PacGrow Healthcare Virtual Conference
Forum: Presentation
Date/Time: Wednesday, August 12, 2020, at 1:45 p.m. ET

A live webcast of the presentations will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 90 days following the presentation.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:

Investor & Media Contact
Sarah Carmody
617-844-8577
scarmody@mersana.com

FAQ

What are the details of Mersana Therapeutics' upcoming investor conferences?

Mersana Therapeutics will present at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 1:00 p.m. ET and at the Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 1:45 p.m. ET.

Where can I watch the presentations by Mersana Therapeutics?

The presentations can be viewed via live webcast on the Investors & Media section of Mersana's website, with archived replays available for approximately 90 days.

What is the focus of Mersana Therapeutics as a biopharmaceutical company?

Mersana Therapeutics specializes in developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs.

What are the lead product candidates of Mersana Therapeutics?

Mersana's lead product candidates include XMT-1536, targeting ovarian cancer and NSCLC adenocarcinoma, and XMT-1592, targeting NaPi2b-expressing tumors.